Exelixis files U.S. application for expanded use of Cabometyx

|By:, SA News Editor

Exelixis (NASDAQ:EXEL) completes the submission of its U.S. marketing application seeking approval for CABOMETYX (cabozantinib) for treatment-experienced patients with advanced hepatocellular carcinoma (liver cancer).

The data supporting the filing was generated in the Phase 3 CELESTIAL study.

The FDA first approved CABOMETYX in April 2016 for advanced kidney cancer.

Subscribe for full text news in your inbox